A multi-biomarker panel, notably including SDF1, AD, and IL-39, emerges as a promising discovery-phase signature that, following independent external validation, may provide a non-invasive method for monitoring therapeutic response, but further validation is needed before clinical use.
AbdulQader M. AbdulQader, M. K. Abd, Kawthar Amer al-Shamari et al.· Asian Pacific Journal of Can...· 0 citations
PFKFB3 is a druggable regulator of fructose-2,6-bisphosphate production, glycolytic flux, angiogenic metabolism, and tumour-cell survival signalling. This study redesigned the AZ67 allosteric scaffold to prioritise computational leads for anticancer metabolic drug discovery. ChemoDOTS enumeration produced 575,760 virtu...
A. Mohammed, Jameelah K. T. Al-Isawi, M. K. Abd· Journal of Cancer Research U...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.